Skip to content
Open access · OA via OpenAlex

A de novo compound targeting α-synuclein improves deficits in models of Parkinson's disease

Wolfgang Wrasidlo, Igor F. Tsigelny, Diana L. Price, Garima Dutta, Edward M. Rockenstein, Thomas C. Schwarz, Karin Ledolter, Douglas W. Bonhaus, Amy Paulino, Simona Eleuteri, Åge Aleksander Skjevik, Valentina L. Kouznetsova, Brian J. Spencer, Paula Desplats, Tania Gonzalez

Brain · 2016 · ▲ 151 citations

Abstract

Abnormal accumulation and propagation of the neuronal protein α-synuclein has been hypothesized to underlie the pathogenesis of Parkinson's disease, dementia with Lewy bodies and multiple system atrophy. Here we report a de novo-developed compound (NPT100-18A) that reduces α-synuclein toxicity through a novel mechanism that involves displacing α-synuclein from the membrane. This compound interacts with a domain in the C-terminus of α-synuclein. The E83R mutation reduces the compound interaction with the 80-90 amino acid region of α-synuclein and prevents the effects of NPT100-18A. In vitro studies showed that NPT100-18A reduced the formation of wild-type α-synuclein oligomers in membranes, reduced the neuronal accumulation of α-synuclein, and decreased markers of cell toxicity. In vivo studies were conducted in three different α-synuclein transgenic rodent models. Treatment with NPT100-18A ameliorated motor deficits in mThy1 wild-type α-synuclein transgenic mice in a dose-dependent manner at two independent institutions. Neuropathological examination showed that NPT100-18A decreased the accumulation of proteinase K-resistant α-synuclein aggregates in the CNS and was accompanied by the normalization of neuronal and inflammatory markers. These results were confirmed in a mutant line of α-synuclein transgenic mice that is prone to generate oligomers. In vivo imaging studies of α-synuclein-GFP transgenic mice using two-photon microscopy showed that NPT100-18A reduced the cortical synaptic accumulation of α-synuclein within 1 h post-administration. Taken together, these studies support the notion that altering the interaction of α-synuclein with the membrane might be a feasible therapeutic approach for developing new disease-modifying treatments of Parkinson's disease and other synucleinopathies.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.1093/brain/aww238
Canonical
link ↗
Fetched
2026-10-21 MST

Cite this

APA
Wrasidlo, W., Tsigelny, I.F., Price, D.L., Dutta, G., Rockenstein, E.M., Schwarz, T.C., Ledolter, K., Bonhaus, D.W., Paulino, A., Eleuteri, S., Skjevik, �.A., Kouznetsova, V.L., Spencer, B.J., Desplats, P., Gonzalez, T., Trejo, M., Overk, C., Winter, S., Zhu, C., &amp; Chesselet, M. (2016). A de novo compound targeting α-synuclein improves deficits in models of Parkinson's disease. <em>Brain</em>. https://doi.org/10.1093/brain/aww238
Vancouver
Wrasidlo W, Tsigelny IF, Price DL, Dutta G, Rockenstein EM, Schwarz TC, et al. A de novo compound targeting α-synuclein improves deficits in models of Parkinson's disease. Brain. 2016. doi:10.1093/brain/aww238.
BibTeX
@article{wolfgang2016Adenov, title = {A de novo compound targeting α-synuclein improves deficits in models of Parkinson's disease}, author = {Wolfgang Wrasidlo and Igor F. Tsigelny and Diana L. Price and Garima Dutta and Edward M. Rockenstein and Thomas C. Schwarz and Karin Ledolter and Douglas W. Bonhaus and Amy Paulino and Simona Eleuteri and Åge Aleksander Skjevik and Valentina L. Kouznetsova and Brian J. Spencer and Paula Desplats and Tania Gonzalez and Margarita Trejo and Cassia Overk and Stefan Winter and Chunni Zhu and Marie‐Françoise Chesselet and Dieter Meier and Herbert Moessler and Robert Konrat and Eliezer Masliah}, journal = {Brain}, year = {2016}, doi = {10.1093/brain/aww238}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings